Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xlucane
- Development stage
- Phase 3
- Lead developer
- Xbrane
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Ophthalmic
01
Overview
Xlucane is a biosimilar to Lucentis (ranibizumab), developed for the treatment of serious retinal vascular disorders, primarily wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The active ingredient is ranibizumab, a monoclonal antibody fragment that inhibits angiogenesis by binding to and neutralizing vascular endothelial growth factor A (VEGF-A), thereby preventing excessive formation of blood vessels in the retina. Xlucane has demonstrated equivalent efficacy and safety compared to Lucentis in pivotal phase III clinical trials. It is being developed and commercialized through partnerships involving Xbrane Biopharma, STADA, Valorum Biologics, and Helvetic BioPharma for various global markets[1][2][5][6][7].
- Brand names
- xlucane
- Other names
- ranibizumab biosimilar
02
Targets
Beyond the preview
Go deeper on xlucane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xlucane.